Javascript must be enabled to continue!
Perioperative pain management and outcomes in patients who discontinued or continued pre-existing buprenorphine therapy
View through CrossRef
Objective: This study compared opioid utilization and clinical outcomes in surgical patients receiving maintenance buprenorphine therapy who discontinued versus those who continued buprenorphine treatment perioperatively. Lack of high-quality evidence, conflicting results in previous studies, and the possible need for reinduction after discontinuing therapy present clinicians with the complicated dilemma of choosing the best strategy to control post-operative pain in patients receiving buprenorphine.Design: A multicenter, retrospective cohort study.Participants: Hospitalized patients between January 1, 2017 and December 12, 2019 who underwent any type of surgery, had a documentation of an outpatient buprenorphine prescription or inpatient order, and received buprenorphine for 5 or more days prior to the procedure were included.Main outcome measure(s): The primary objective was to compare mean 24-hour morphine milligram equivalent (MME) utilization post-operatively between patients who discontinued buprenorphine preoperatively versus those who continued therapy throughout the perioperative period.Results: Fifty-one patients met the inclusion criteria for this study. Of these, 42 patients were continued on buprenorphine through surgery, while nine patients had a documentation of discontinuation preoperatively. The 24-hour post-operative MME utilization (interquartile range) was 58.8 (18-100.8) in patients who continued therapy through surgery versus 152.6 (114.5-236) in patients who discontinued therapy preoperatively (p = 0.005). There were no significant differences in post-operative pain scores or length of stay between groups.Conclusion: Post-operative opioid use was significantly lower in patients who continued buprenorphine compared with those who discontinued buprenorphine preoperatively.
Title: Perioperative pain management and outcomes in patients who discontinued or continued pre-existing buprenorphine therapy
Description:
Objective: This study compared opioid utilization and clinical outcomes in surgical patients receiving maintenance buprenorphine therapy who discontinued versus those who continued buprenorphine treatment perioperatively.
Lack of high-quality evidence, conflicting results in previous studies, and the possible need for reinduction after discontinuing therapy present clinicians with the complicated dilemma of choosing the best strategy to control post-operative pain in patients receiving buprenorphine.
Design: A multicenter, retrospective cohort study.
Participants: Hospitalized patients between January 1, 2017 and December 12, 2019 who underwent any type of surgery, had a documentation of an outpatient buprenorphine prescription or inpatient order, and received buprenorphine for 5 or more days prior to the procedure were included.
Main outcome measure(s): The primary objective was to compare mean 24-hour morphine milligram equivalent (MME) utilization post-operatively between patients who discontinued buprenorphine preoperatively versus those who continued therapy throughout the perioperative period.
Results: Fifty-one patients met the inclusion criteria for this study.
Of these, 42 patients were continued on buprenorphine through surgery, while nine patients had a documentation of discontinuation preoperatively.
The 24-hour post-operative MME utilization (interquartile range) was 58.
8 (18-100.
8) in patients who continued therapy through surgery versus 152.
6 (114.
5-236) in patients who discontinued therapy preoperatively (p = 0.
005).
There were no significant differences in post-operative pain scores or length of stay between groups.
Conclusion: Post-operative opioid use was significantly lower in patients who continued buprenorphine compared with those who discontinued buprenorphine preoperatively.
.
Related Results
Assessing the Safety and Efficacy of Converting Adults with Sickle Cell Disease from Full Agonist Opioids to Buprenorphine
Assessing the Safety and Efficacy of Converting Adults with Sickle Cell Disease from Full Agonist Opioids to Buprenorphine
Abstract
Background: The management of pain in adults with sickle cell disease (SCD) is complex, with the intermingling of both acute vaso-occlusive events and chron...
A prospective, randomized trial of the effect of buprenorphine continuation versus dose reduction on pain control and post-operative opioid use
A prospective, randomized trial of the effect of buprenorphine continuation versus dose reduction on pain control and post-operative opioid use
Introduction:
An increasing number of individuals are taking buprenorphine for management of opioid use disorder (OUD). Pain control can be challenging when these patie...
Differential Diagnosis of Neurogenic Thoracic Outlet Syndrome: A Review
Differential Diagnosis of Neurogenic Thoracic Outlet Syndrome: A Review
Abstract
Thoracic outlet syndrome (TOS) is a complex and often overlooked condition caused by the compression of neurovascular structures as they pass through the thoracic outlet. ...
The Effects of Prenatal Buprenorphine Exposure on the Neurobehavioral Development of the Child
The Effects of Prenatal Buprenorphine Exposure on the Neurobehavioral Development of the Child
Background: Current guidelines for pregnant women with substance use disorder advise prenatal maintenance of opioid agonist therapy with either buprenorphine or methadone. Despite ...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Trends in Access to Medications for Opioid Use Disorder
Trends in Access to Medications for Opioid Use Disorder
ImportanceMedicaid, the largest payer for medications for opioid use disorder (MOUD), disenrolled more than 19.1 million individuals by March 2024 after the continuous coverage req...
Buprenorphine-Precipitated Withdrawal Among Hospitalized Patients Using Fentanyl
Buprenorphine-Precipitated Withdrawal Among Hospitalized Patients Using Fentanyl
ImportanceBuprenorphine treatment of opioid use disorder (OUD) is safe and effective, but opioid withdrawal during treatment initiation is associated with poor retention in care. A...
Buprenorphine supply by community pharmacists in Victoria, Australia: perceptions, experiences and key issues identified
Buprenorphine supply by community pharmacists in Victoria, Australia: perceptions, experiences and key issues identified
AbstractBuprenorphine is dispensed primarily in community pharmacies in Victoria, with buprenorphine prescribing expanding nationally. The aim of this paper was to examine issues t...

